Fundamental Analysis of BIOTRICITY INC(NASDAQ:BTCY) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to BTCY. BTCY was compared to 40 industry peers in the Health Care Technology industry. Both the profitability and financial health of BTCY have multiple concerns. BTCY is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BTCY has reported negative net income.

In the past year BTCY has reported a negative cash flow from operations.

In the past 5 years BTCY always reported negative net income.

BTCY had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -280.45%, BTCY is not doing good in the industry: 92.31% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-280.45%
ROE	N/A
ROIC	N/A

ROA(3y)-283.89%

ROA(5y)-634.15%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of BTCY (65.54%) is better than 61.54% of its industry peers.

BTCY's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for BTCY so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	65.54%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y17.82%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BTCY does not have a ROIC to compare to the WACC, probably because it is not profitable.

BTCY has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, BTCY has less shares outstanding

Compared to 1 year ago, BTCY has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -35.47, we must say that BTCY is in the distress zone and has some risk of bankruptcy.

BTCY's Altman-Z score of -35.47 is on the low side compared to the rest of the industry. BTCY is outperformed by 92.31% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-35.47

ROIC/WACCN/A

WACC11.31%

2.3 Liquidity

A Current Ratio of 0.21 indicates that BTCY may have some problems paying its short term obligations.

With a Current ratio value of 0.21, BTCY is not doing good in the industry: 92.31% of the companies in the same industry are doing better.

A Quick Ratio of 0.10 indicates that BTCY may have some problems paying its short term obligations.

BTCY's Quick ratio of 0.10 is on the low side compared to the rest of the industry. BTCY is outperformed by 94.87% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.21
Quick Ratio	0.1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.82% over the past year.

BTCY shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.43%.

Measured over the past years, BTCY shows a very strong growth in Revenue. The Revenue has been growing by 89.35% on average per year.

EPS 1Y (TTM)26.82%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q37.22%

Revenue 1Y (TTM)28.43%

Revenue growth 3Y89.35%

Revenue growth 5YN/A

Revenue growth Q2Q20.85%

3.2 Future

The Earnings Per Share is expected to grow by 34.33% on average over the next years. This is a very strong growth

Based on estimates for the next years, BTCY will show a very strong growth in Revenue. The Revenue will grow by 22.69% on average per year.

EPS Next Y29.55%

EPS Next 2Y34.33%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year26.32%

Revenue Next 2Y22.69%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BTCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BTCY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BTCY's earnings are expected to grow with 34.33% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y34.33%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BTCY does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOTRICITY INC

NASDAQ:BTCY (5/14/2024, 7:24:02 PM)

After market: 1.11 -0.01 (-0.89%)

1.12

+0.03 (+2.75%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Technology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap10.43M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-280.45%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	65.54%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover2.12

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.21
Quick Ratio	0.1
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)26.82%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y29.55%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)28.43%

Revenue growth 3Y89.35%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BIOTRICITY INC (BTCY)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens